ofloxacin + MSI-78
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Foot Ulcers
Conditions
Diabetic Foot Ulcers
Trial Timeline
Aug 1, 1994 → Jul 1, 1996
NCT ID
NCT00563394About ofloxacin + MSI-78
ofloxacin + MSI-78 is a phase 3 stage product being developed by Abeona Therapeutics for Diabetic Foot Ulcers. The current trial status is completed. This product is registered under clinical trial identifier NCT00563394. Target conditions include Diabetic Foot Ulcers.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00563394 | Phase 3 | Completed |
| NCT00563433 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetic Foot Ulcers